Business
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025
Expression data from patient-derived xenograft (PDX) mouse models exposed to micvotabart pelidotin (MICVO) indicate gene signatures associated with efficacy, deepening understanding of MOA and potential patient response Combination of a mouse analog of MICVO and a mouse anti-PD-1 therapy in a syngeneic model resulted in significantly greater tumor regression than either treatment alone Company advances MICVO into monotherapy and combination clinical trials with Merck’s anti-PD-1 therapy, Keytrud
About this update from Pyxis Oncology, Inc.
[{"type":"image","alt":"Pyxis Oncology","displaySize":"","headline":null,"caption":"Pyxis Oncology","className":"","disableSlideshowImg":false,"size":{"original":{"width":203,"height":105,"url":"https://media.zenfs.com/en/globenewswire.com/c663fbbdcef74ec76700a29d86aa098c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IX0t534d6HFsYbdc2gj8WA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTE4NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c663fbbdcef74ec76700a29d86aa098c","width":203,"height":105}},"lazy":false},{"type":"text","content":"Expression data from patient-derived xenograft (PDX) mouse models exposed to micvotabart pelidotin (MICVO) indicate gene signatures associated with efficacy, deepening understanding of MOA and potential patient response","length":219,"tagName":"p"},{"type":"text","content":"Combination of a mouse analog of MICVO and a mouse anti-PD-1 therapy in a syngeneic model resulted in significantly greater tumor regression than either treatment alone","length":168,"tagName":"p"},{"type":"text","content":"Company advances MICVO into monotherapy and combination clinical trials with Merck’s anti-PD-1 therapy, Keytruda® (pembrolizumab), targeting recurrent and metastatic head and neck squamous cell carcinoma; preliminary data expected in 2H2025 and 1H2026","length":251,"tagName":"p"},{"type":"text","content":"BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, announced today that the Company will present new, positive preclinical data highlighting the potential of micvotabart pelidotin (MICVO, formerly referred to as PYX-201), a first-in-concept antibody-drug conjugate (ADC) that targets EDB+FN, a non-cellular structural component of the tumor extra-cellular matrix. These data will be presented in two poster sessions at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois, held from April 25 to 30, 2025.","length":665,"tagName":"p"},{"type":"text","content":""We are thrilled to present new preclinical data at AACR25 that further elucidate the innovative mechanism of action of MICVO, our first-in-concept EDB+FN targeting ADC, which leverages a unique non-cellular mechanism to drive anti-tumor activity,” said Lara S. Sullivan, M.D., President, Chief Executive Officer and C...